Unknown

Dataset Information

0

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.


ABSTRACT: Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted life year (QALY) over a 5-year period. Results: Solifenacin 5 mg/day was the dominant treatment strategy (i.e., less costly and more effective) versus tolterodine extended-release (ER) 4 mg/day, fesoterodine 4 and 8 mg/day, oxybutynin ER 10 mg/day and solifenacin 10 mg/day, and was cost-effective (i.e., ICERs below the £30,000 per QALY threshold generally applied in the NHS) versus oxybutynin immediate release (IR) 10 mg/day, tolterodine IR 4 mg/day and trospium chloride 60 mg/day. The probability of solifenacin 5 mg/day being dominant/cost-effective at a willingness-to-pay threshold of £30,000 per QALY was 57-98%. Conclusions: Solifenacin 5 mg/day appears to be a cost-effective strategy for the treatment of OAB over a 5-year timeframe compared with other oral antimuscarinic agents in the UK. These findings are important for decision-makers considering the economic implications of selecting treatments for OAB.

SUBMITTER: Hakimi Z 

PROVIDER: S-EPMC5907635 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.

Hakimi Zalmai Z   Kelleher Con C   Aballéa Samuel S   Maman Khaled K   Nazir Jameel J   Mankowski Colette C   Odeyemi Isaac I  

Journal of market access & health policy 20180320 1


<b>Objective:</b> To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. <b>Study design:</b> In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted lif  ...[more]

Similar Datasets

| S-EPMC7018934 | biostudies-literature
| S-EPMC5434500 | biostudies-literature
| S-EPMC8100008 | biostudies-literature
| S-EPMC4580095 | biostudies-literature
| S-EPMC7685239 | biostudies-literature
| S-EPMC4300413 | biostudies-literature
| S-EPMC5935888 | biostudies-literature
| S-EPMC9289997 | biostudies-literature
| S-EPMC10288955 | biostudies-literature
| S-EPMC8280006 | biostudies-literature